|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Mid Pharma Sector: In-licensing and other externalization strategies |
|
|
|
|
€ 6 080,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Juin 2006 |
Taille du document : |
114 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Pharmaceutical Distribution Outlook 1998-2008
165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
Healthcare In Southern Ireland
40 pages | Mai 2000 |
The Republic Of Ireland Presentation Includes:- The Structure Of The Health Service In The Republic Of Ireland- Capital Expenditure On Health Care In The Republic Of Ireland- Number Of Publicly Funded |
327,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
2 835,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
The Pharmaceutical Outsourcing Outlook 1998-2003
199 pages | Juin 1999 |
The streamlining of pharmaceutical companies that has taken place in recent years has allowed them to focus resources and investment on core specialities.
This, in turn, has led to a greater re |
795,00 €
|
| |
| |
Global Pharmaceutical: a market, company and disease analysis
150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar |
795,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
3 500,00 €
|
| |
| |
Pharmaceutical Packaging: UK
90 pages | Avril 2000 |
· Analyse the changes in demand for pharmaceutical packaging in the UK, over the next 5 years
· Understand the main factors affecting demand
· Examine the struct |
1 249,31 €
|
| |
| |
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth
173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Mid Pharma Sector: In-licensing and other externalization strategies |
|
|
Introduction
Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.
Scope
Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus
Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios
Examination of which types of externalization strategy are most popular in the Mid Pharma peer set
Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe
Highlights
Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the 'Big 6', CNS-focus, CV-focus, small domestic and 'multi-business unit' clusters.
Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the 'Big 6' players located in the middle range, addressing a broad range of therapy areas.
Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier.
Reasons to Purchase
Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition
Identify which companies are appropriate licensing targets on the basis of their 'fit' according to their scale, therapeutic and geographic focus
Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma
|
|
Introduction
Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.
Scope
Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus
Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios
Examination of which types of externalization strategy are most popular in the Mid Pharma peer set
Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe
Highlights
Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the 'Big 6', CNS-focus, CV-focus, small domestic and 'multi-business unit' clusters.
Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the 'Big 6' players located in the middle range, addressing a broad range of therapy areas.
Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier.
Reasons to Purchase
Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition
Identify which companies are appropriate licensing targets on the basis of their 'fit' according to their scale, therapeutic and geographic focus
Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma
|
|
|
PPLSEN
|
|
|
|
|
